BITG.F Stock Overview
Biotage AB (publ) provides solutions and products in the areas of drug discovery and development, analytical testing, and water and environmental testing.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Biotage AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr16.87 |
| 52 Week High | kr16.87 |
| 52 Week Low | kr8.00 |
| Beta | 0.80 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 40.58% |
| 3 Year Change | -23.32% |
| 5 Year Change | 17.15% |
| Change since IPO | 1,366.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| BITG.F | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | 4.1% | 1.2% |
| 1Y | 40.6% | 4.7% | 24.9% |
Return vs Industry: BITG.F exceeded the US Life Sciences industry which returned 5.2% over the past year.
Return vs Market: BITG.F exceeded the US Market which returned 24.7% over the past year.
Price Volatility
| BITG.F volatility | |
|---|---|
| BITG.F Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 6.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BITG.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BITG.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1969 | 674 | Torben Jorgensen | www.biotage.com |
Biotage AB (publ) provides solutions and products in the areas of drug discovery and development, analytical testing, and water and environmental testing. The company offers organic and peptide synthesis solutions; flash chromotherapy, evaporation, and work-up products; flash systems; sample preparation products; plasmid purification solutions; oligo synthesis solutions; and metal scavengers and reagents, as well as accessories and spare parts. It also provides sample preparation solutions in the clinical and bioanalytical, forensic and toxicology, doping control animal and human, environment, and food and agriculture areas, as well as consumables and systems; protein purification solutions, including antibody and tagged proteins purification, automation systems, and custom packing service, as well as ion exchange, reversed phase, normal phase, and gel filtration PhyTip columns.
Biotage AB (publ) Fundamentals Summary
| BITG.F fundamental statistics | |
|---|---|
| Market cap | US$1.20b |
| Earnings (TTM) | US$22.61m |
| Revenue (TTM) | US$171.15m |
53.0x
P/E Ratio7.0x
P/S RatioIs BITG.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BITG.F income statement (TTM) | |
|---|---|
| Revenue | kr1.86b |
| Cost of Revenue | kr713.00m |
| Gross Profit | kr1.15b |
| Other Expenses | kr903.00m |
| Earnings | kr246.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 25, 2024
| Earnings per share (EPS) | 3.07 |
| Gross Margin | 61.71% |
| Net Profit Margin | 13.21% |
| Debt/Equity Ratio | 4.1% |
How did BITG.F perform over the long term?
See historical performance and comparison